Noopept (INN omberacetam; development codes GVS-111, SGS-111; CAS 157115-85-0) is a synthetic N-phenylacetyl-L-prolylglycine ethyl ester — a dipeptide-derived, racetam-class nootropic that is orally active and, despite the "peptide" framing, behaves as a small molecule rather than an injectable peptide drug. It was developed in Russia at the Zakusov Institute of Pharmacology and is a registered medicine there for cognitive disorders of vascular and post-traumatic origin. That detail sets Noopept apart from most research-chemical nootropics: it has published human clinical data, not just animal work and forum reports.
This article sorts the claimed benefits by source class — what Russian human trials reported, what is preclinical (animal and cell-model), and what is purely community-reported. The honest summary up front: the human evidence points in a positive direction but is thin in rigor — small, mostly open-label or piracetam-comparator, Russian-language, and concentrated near the originating research group. No retractions or misconduct findings were identified for the Noopept literature, which distinguishes it from some other research nootropics; its principal limitation is depth and independence of evidence, not integrity.
Research-context information only. Noopept is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
How Noopept Works
The proposed mechanism is preclinical, not directly proven in humans. After oral dosing, Noopept is rapidly metabolized — substantially within the brain — to cycloprolylglycine (cPG), a cyclic dipeptide of proline and glycine that already occurs naturally in the mammalian brain. The framing in the originating group's work is that Noopept amplifies a naturally present modulatory signal rather than introducing a wholly foreign one. cPG is described as a positive AMPA-receptor modulator that raises BDNF and NGF; Gudasheva et al. 2001 (PMID 11550054) reported a dose-dependent anxiolytic effect of cPG in the elevated plus-maze, with the L-enantiomer active and the D-form inactive.
Around that core, the preclinical record describes glutamatergic (AMPA/NMDA) modulation, enhanced cholinergic transmission, upregulation of neurotrophic factors, and antioxidant/neuroprotective activity. One point of community confusion worth correcting: Noopept does not have a long half-life. Rat pharmacokinetic work (Boyko, Zherdev & Shevchenko 2018, PMID 30378564) found plasma cPG fits a two-compartment model with a short terminal half-life (on the order of ~80 minutes for cPG). The parent compound and its metabolite clear quickly; the proposed durable effects are attributed to downstream neurotrophic signaling, not to a long-circulating drug. The honest caveat is that much of this mechanistic core comes from a single Russian originating group and is consistent but not widely replicated outside it.
Cognitive Benefits in Mild Cognitive Impairment (Clinical — Russian Trials)
The strongest human signal is in disease populations, not healthy enhancement. Neznamov & Teleshova 2008 (PMID 18697252) compared Noopept against piracetam in patients with mild-to-moderate cognitive impairment from organic brain disease of vascular and traumatic origin. The reported regimen was Noopept 10 mg twice daily (20 mg/day) for roughly 56 days versus piracetam 1200 mg/day. The authors described Noopept efficacy as at least comparable to piracetam, and in some asthenic and post-concussional subgroups significantly greater, alongside an anxiolytic and regulatory effect. This comparative trial is the source of the trial-derived 20 mg/day figure.
A separate EEG and clinical characterization (Bochkarev, Teleshova, Siuniakov, Davydova & Neznamov 2008, PMID 19008801) profiled Noopept in post-traumatic and vascular mild cognitive impairment, describing nonspecific cortical activation plus an anxiolytic component that was more pronounced in vascular cases. These are real human data, but they are small and mostly open-label or active-comparator rather than large placebo-controlled trials, they are Russian-language, and they cluster near the originating program. Read them as supportive and directionally consistent, not as Western-RCT-grade proof — and as findings in impaired patients, not in healthy users seeking cognitive enhancement.
30mg · sold research-use-only · we may earn a commission
Anxiolytic and Regulatory Effects (Clinical + Preclinical)
A recurring thread across both the human and animal literature is an anxiolytic, mood-regulating component reported alongside the cognitive effects. In the clinical work above, the trial authors described a "regulatory" anxiolytic effect rather than pure stimulation (PMID 18697252, 19008801). The proposed biological basis sits in the metabolite: Gudasheva et al. 2001 (PMID 11550054) reported that cycloprolylglycine produced a dose-dependent anxiolytic effect in the elevated plus-maze, which the originating group ties to the calming component seen clinically.
It is worth flagging that the community picture here is not uniform. While trial reports and many anecdotal accounts describe a calming or anxiolytic quality, a meaningful share of community users instead describe Noopept as stimulating or mildly anxiogenic, and some report no clear effect at all. None of the community reports are placebo-controlled, and expectation effects are unquantified. The anxiolytic signal is best described as documented in the Russian trials and supported by a preclinical mechanism, with community experience varying in both direction and magnitude.
Neuroprotection and Anti-Amyloid Activity (Preclinical)
Outside the human trials, the preclinical record describes a fairly broad neuroprotective and anti-amyloid profile — though entirely in animal and cell models. Ostrovskaya, Vakhitova et al. 2014 (PMID 25096780), published in the Journal of Biomedical Science, tested Noopept in PC12 cells exposed to amyloid-beta (Aβ25-35): pretreatment reduced apoptosis, lowered reactive oxygen species and intracellular calcium, restored mitochondrial membrane potential, and attenuated tau hyperphosphorylation at Ser396 — an Alzheimer's-relevant set of readouts, in vitro.
In a whole-animal Alzheimer's-type model, Bobkova, Gruden et al. 2005 (PMID 16277202) reported that Noopept improved Morris water-maze spatial memory in olfactory-bulbectomized mice and stimulated production of antibodies to prefibrillar β-amyloid(25-35), proposing a dual cognitive and immunomodulatory action. Separately, Zarubina & Shabanov 2009 (PMID 19529857) reported that Noopept reduced post-ischemic functional and metabolic disturbances in rat brain across animals of differing hypoxia sensitivity, consistent with an antioxidant/neuroprotective effect.
The pattern across these studies is more consistent and broader than many research nootropics manage — memory, neuroprotection, anti-amyloid, and anxiolytic signals all point the same way. The two caveats that keep it preclinical are that the work is heavily weighted toward the originating group and that it sits in disease and injury models rather than healthy cognitive enhancement. None of it has been confirmed as a human mechanism.
Who It's Been Studied In, and What People Report
The foundational oral-route evidence comes from Ostrovskaya et al. 2001 (PMID 11782792), which established that GVS-111 (Noopept) retained antiamnesic activity after oral administration in rats (effective roughly 0.5-10 mg/kg) — the basis for the oral human route. The human studies that followed were conducted in impaired populations: mild cognitive impairment of vascular and post-traumatic origin, and stroke. Amelin, Ilyukhina & Shmonin 2011 (PMID 22500312) ran an open prospective study of about 60 stroke patients on roughly 20 mg/day for up to 12 months and reported improved cognitive function and "a high level of safety." Open-label design means this is supportive, not definitive.
On the community side, a dose people actually take does exist and should be reported plainly. Community and vendor sources most commonly cite 10-30 mg/day, usually split into 2-3 small doses, with new users frequently starting around 10 mg. That range overlaps the trial-derived 20 mg/day from the Russian studies, which is part of why Noopept's community dosing is unusually well-anchored for a research chemical — but the spread above 20 mg/day is community/vendor-derived, not trial-validated. Community users commonly report subtle onset within about 15-60 minutes (mild focus or clarity), with the more valued effects — verbal fluency, memory consolidation, reduced anxiety — described as building over days to a few weeks of consistent use. These reports are inconsistent and not placebo-controlled. Noopept is sold by vendors such as Swiss Chems as a research chemical — research use only, not for human consumption — in powder and capsule form; because it is orally active, there is no bacteriostatic-water reconstitution step.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Yes — unlike most research nootropics. Russian trials in mild cognitive impairment of vascular or post-traumatic origin and in stroke patients reported cognitive and anxiolytic benefits (PMID 18697252, 19008801, 22500312). They are mostly small, open-label or piracetam-comparator, Russian-language, and near the originating research group — supportive but not Western-RCT grade.
What dose do people actually use?
Community and vendor sources most commonly cite 10-30 mg/day, usually split into 2-3 doses, with new users starting around 10 mg. The dose used in the Russian trials was 20 mg/day (10 mg twice daily). So a clinically studied dose exists (20 mg/day); the wider 10-30 mg/day range is community/vendor-derived, not trial-validated.
Is the '1000x more potent than piracetam' claim true?
It refers to potency by dose — Noopept is active at tens of milligrams versus piracetam's grams — not to being 1000x more effective. It is a dosing-potency statement, not an efficacy multiplier.
Related Reading
Noopept dosing guide — the trial-derived 20 mg/day figure versus the wider community-reported range, with research-context framing.
Noopept side effects — trial-reported adverse events versus the community headache-and-choline pattern.
Noopept results timeline — what the Russian trials describe over weeks versus the fast-but-subtle community onset.
Semax benefits — the Russian nootropic peptide often discussed alongside Noopept, with its own clinical-trial base.
NSI-189 benefits — a neurogenesis-focused research compound whose Phase 2 depression trial missed its primary endpoint.
Cerebrolysin benefits — a porcine-brain neuropeptide mixture given by injection, with a larger but genuinely contested clinical-trial base.
References
Neznamov GG, Teleshova ES. Comparative trial of Noopept versus piracetam in mild-to-moderate cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18697252. (Clinical — source of the 20 mg/day regimen.)
Amelin AV, Ilyukhina AYu, Shmonin AA. Open prospective stroke study, ~20 mg/day. Zh Nevrol Psikhiatr Im S S Korsakova. 2011. PMID 22500312. (Clinical — cognition + safety.)
Bochkarev VK, et al. Clinical and EEG characterization in post-traumatic/vascular MCI. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 19008801. (Clinical — activation + anxiolytic effect.)
Gudasheva TA, et al. Endogenous metabolite cycloprolylglycine: anxiolytic in the elevated plus-maze. Bull Exp Biol Med. 2001. PMID 11550054. (Preclinical — metabolite basis.)
Ostrovskaya RU, Vakhitova YV, et al. Neuroprotection in an Aβ25-35 PC12 cell model. J Biomed Sci. 2014. PMID 25096780. (Preclinical — anti-amyloid, tau-Ser396.)
Bobkova NV, Gruden MA, et al. Spatial memory and anti-β-amyloid antibody production in bulbectomized mice. Eksp Klin Farmakol. 2005. PMID 16277202. (Preclinical — AD model.)
Zarubina IV, Shabanov PD. Anti-ischemic/antioxidant neuroprotection in rat brain. Bull Exp Biol Med. 2009. PMID 19529857. (Preclinical — ischemia.)
Ostrovskaya RU, et al. GVS-111 retains antiamnesic activity after oral dosing in rats. Bull Exp Biol Med. 2001. PMID 11782792. (Preclinical — oral route foundation.)
